These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 38756778)

  • 1. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
    Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
    Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
    Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
    Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.
    Dai G; He L; Yan Q; Li Y; Huang Y; Li B; Wang G
    Front Oncol; 2023; 13():1167516. PubMed ID: 37456237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
    Jiao Y; Liu M; Luo N; Guo H; Li J
    Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
    Yin X; Liu X; Ren F; Meng X
    Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
    Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
    Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
    Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
    J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
    Su H; Yu C; Ma X; Song Q
    Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
    Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
    Front Genet; 2022; 13():949989. PubMed ID: 35938033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
    Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J
    Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
    Fu L; Chen P; Wang S; Liu W; Chen Z; Chen H; Fu Z
    Anticancer Drugs; 2022 Jan; 33(1):e741-e746. PubMed ID: 34338239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.
    Jin C; Yang B
    Case Rep Oncol; 2020; 13(2):601-605. PubMed ID: 32595469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
    Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report.
    Jin Y; Xiao W; Wang X; Cui Y; Li B; Liu X
    Medicine (Baltimore); 2021 Oct; 100(42):e27581. PubMed ID: 34678907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
    Qian X; Wang Y; Liu F; Yuan Y; Fang C; Zhang X; Yuan S; Chen R; Yu B; Wang T; Yin Y; Li Y
    Front Immunol; 2022; 13():956982. PubMed ID: 36389780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.